Yanyan Lou

List of Publications by Year
in descending order

47 papers	3,363 citations	279798 23 h-index	243625 44 g-index
47 all docs	47 docs citations	47 times ranked	5371 citing authors

#	Article	IF	Citations
1	Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors. Clinical Cancer Research, 2022, 28, 479-488.	7.0	16
2	Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. , 2022, 10, e003779.		34
3	Humoral Responses After SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer Patients. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2022, 6, 120-125.	2.4	10
4	Carbon ion radiotherapy in the management of nonâ€small cell lung cancer. Precision Radiation Oncology, 2022, 6, 69-74.	1.1	3
5	BRAF p.V600E associated poly-neoplastic syndrome. Rare Tumors, 2021, 13, 203636132110129.	0.6	4
6	Next generation of immune checkpoint inhibitors and beyond. Journal of Hematology and Oncology, 2021, 14, 45.	17.0	293
7	Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. Journal of the National Cancer Institute, 2021, 113, 1396-1404.	6.3	56
8	A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 3630-3640.	7.0	11
9	Immunotherapies targeting stimulatory pathways and beyond. Journal of Hematology and Oncology, 2021, 14, 78.	17.0	23
10	Immuneâ€related hematologic adverse events in the context of immune checkpoint inhibitor therapy. American Journal of Hematology, 2021, 96, E362-E367.	4.1	4
11	Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. Journal of Hematology and Oncology, 2021, 14, 108.	17.0	127
12	Association of Race, Socioeconomic Factors, and Treatment Characteristics With Overall Survival in Patients With Limited-Stage Small Cell Lung Cancer. JAMA Network Open, 2021, 4, e2032276.	5.9	22
13	Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 751209.	2.8	10
14	Epidemiologic and Clinical Analysis of Tumor Mutational Burden (TMB) in Acute Myeloid Leukemia (AML): Exome Sequencing Study of the Mayo Clinic AML Epidemiology Cohort (MCAEC). Blood, 2021, 138, 3437-3437.	1.4	0
15	Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR. Frontiers in Oncology, 2021, 11, 750657.	2.8	32
16	Profiling of immune features to predict immunotherapy efficacy. Innovation(China), 2021, 3, 100194.	9.1	13
17	Survival of Black and White Patients With Stage IV Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 773958.	2.8	2
18	Influence of Sociodemographic Factors on Treatment Decisions in Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e115-e129.	2.6	19

#	Article	IF	Citations
19	Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches. Radiotherapy and Oncology, 2020, 144, 165-179.	0.6	42
20	Patients with high-grade alectinib-induced skin rash: How do we desensitize these patients? A case report and review of literature. SAGE Open Medical Case Reports, 2020, 8, 2050313X2096689.	0.3	3
21	Immune-Related Hematologic Adverse Events in the Context of Checkpoint Inhibitors. Blood, 2020, 136, 31-32.	1.4	1
22	Emerging therapeutic agents for advanced non-small cell lung cancer. Journal of Hematology and Oncology, 2020, 13, 58.	17.0	161
23	Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC.. Journal of Clinical Oncology, 2020, 38, 3011-3011.	1.6	1
24	Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma. BMC Immunology, 2019, 20, 43.	2.2	6
25	Correlation between immunohistochemistry and RICTOR fluorescence in situ hybridization amplification in small cell lung carcinoma. Human Pathology, 2019, 93, 74-80.	2.0	10
26	Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy. Nature Metabolism, 2019, 1, 431-444.	11.9	158
27	Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. Immunotherapy, 2019, 11, 577-584.	2.0	18
28	Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials. Clinical Cancer Research, 2019, 25, 4422-4430.	7.0	6
29	Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?. Oncologist, 2019, 24, e1148-e1155.	3.7	81
30	Cancer immunotherapy beyond immune checkpoint inhibitors. Journal of Hematology and Oncology, 2018, 11, 8.	17.0	174
31	Comprehensive Characterization of Alternative Polyadenylation in Human Cancer. Journal of the National Cancer Institute, 2018, 110, 379-389.	6.3	111
32	Next generation of immune checkpoint therapy in cancer: new developments and challenges. Journal of Hematology and Oncology, 2018, 11, 39.	17.0	597
33	The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy. Cell Systems, 2018, 6, 314-328.e2.	6.2	183
34	Post-operative radiation therapy in locally advanced non-small cell lung cancer and the impact of sequential versus concurrent chemotherapy. Translational Lung Cancer Research, 2018, 7, S171-S175.	2.8	1
35	Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. , 2018, 6, 129.		95
36	Survival trends among nonâ€smallâ€cell lung cancer patients over a decade: impact of initial therapy at academic centers. Cancer Medicine, 2018, 7, 4932-4942.	2.8	25

#	Article	IF	Citations
37	MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design. BMC Genomics, 2018, 19, 582.	2.8	42
38	Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States. Pharmacoeconomics, 2017, 35, 831-844.	3.3	115
39	Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States. Journal of Medical Economics, 2017, 20, 140-150.	2.1	44
40	Emerging therapeutic agents for lung cancer. Journal of Hematology and Oncology, 2016, 9, 138.	17.0	77
41	Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clinical Lung Cancer, 2016, 17, e5-e11.	2.6	39
42	Molecular basis of antibody binding to mucin glycopeptides in lung cancer. International Journal of Oncology, 2016, 48, 587-594.	3.3	13
43	Epithelialâ€“Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clinical Cancer Research, 2016, 22, 3630-3642.	7.0	353
44	Agonistic Antibody to CD40 Boosts the Antitumor Activity of Adoptively Transferred T Cells In Vivo. Journal of Immunotherapy, 2012, 35, 276-282.	2.4	31
45	Antitumor Activity Mediated by CpG. Journal of Immunotherapy, 2011, 34, 279-288.	2.4	59
46	Plasmacytoid Dendritic Cells Synergize with Myeloid Dendritic Cells in the Induction of Antigen-Specific Antitumor Immune Responses. Journal of Immunology, 2007, 178, 1534-1541.	0.8	122
47	Dendritic Cells Strongly Boost the Antitumor Activity of Adoptively Transferred T Cells In vivo. Cancer Research, 2004, 64, 6783-6790.	0.9	116